Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.4 EUR | -0.81% | +7.31% | -51.36% |
14/05 | Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment | MT |
14/05 | Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease | CI |
Sales 2024 * | 874M 950M 79.3B | Sales 2025 * | 1.04B 1.13B 94.12B | Capitalization | 1.86B 2.02B 169B |
---|---|---|---|---|---|
Net income 2024 * | -29M -31.51M -2.63B | Net income 2025 * | 34M 36.94M 3.08B | EV / Sales 2024 * | 2.43 x |
Net Debt 2024 * | 269M 292M 24.4B | Net Debt 2025 * | 142M 154M 12.86B | EV / Sales 2025 * | 1.93 x |
P/E ratio 2024 * |
-63.1
x | P/E ratio 2025 * |
33.2
x | Employees | 5,061 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
1 day | -0.91% | ||
1 week | +7.31% | ||
Current month | +6.26% | ||
1 month | -21.77% | ||
3 months | -24.26% | ||
6 months | -43.29% | ||
Current year | -51.36% |
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07/23/07 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19/19/19 |
Chairman | 63 | 17/14/17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 17 M€ | -.--% | - | |
2.59% | 202 M€ | -.--% | ||
0.21% | 79 M€ | -.--% | ||
0.15% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
16/24/16 | 10.35 | -1.24% | 692 656 |
15/24/15 | 10.48 | +2.04% | 1,405,214 |
14/24/14 | 10.27 | +3.01% | 1,830,577 |
13/24/13 | 9.97 | +4.73% | 2,080,093 |
10/24/10 | 9.52 | -1.30% | 1,141,574 |
Delayed Quote Xetra, May 16, 2024 at 05:33 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.36% | 2.02B | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.39% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- EVT Stock